



Faculty of Health Science, Department of Pharmacy 
 
Collateral Sensitivity and Resistance Networks in 
















The experimental work presented in this thesis was performed at the Microbial 
Pharmacology and Population Biology Research Group, Department of Pharmacy, 
University of Tromsø, and was carried out between October 2014 and April 2015. 
I want to appoint a special thanks to the main supervisor and Associate Professor Pål J. 
Johnsen for including me warmly to the research group and introducing me to the world 
of science. This has been the most hectic and frustrating year of my life, but at the same 
time the greatest and most instructive. Thank you. 
I am eternally grateful to co-supervisor and Ph.D. student Julia Kloos for caring and 
helping me a lot with laboratory and thesis questions. Sie sind die freundlichsten der 
Welt. 
Thanks to Ph.D. student Ane Utnes with lab-etiquette, and a very big thank you to Postdoc 
Nicole Podnecky helping me with the thesis. You rock! 
I also want to thank the rest of the research group: Ørjan, Raul, Elizabeth, Vidar, Joachim, 
Chiara and Sören. You have the nicest work environment. Every workplace should envy 
you! 
I also want to thank Lilli, the best entertainer during endless hours in the lab! Go team 
collateral!  Thank you “team epistasis” - Gina and Jonathan - for making this year so 
great. A big thank you to the three of you   
I also want to thank the best family in the world. My dearest mom for numerous phone 
calls and loads of motivation, the best medicine is hearing your voice. A big thanks to my 
dad, the most engaged person in the world. Thank you for following me close during 
eighteen years of schooling. I also want to thank my siblings, Anders, Guro and especially, 
Master of Pharmacy, Nina. I would not have done it without the five of you. 
A huge thank you to “farmasijentan” – I am going to miss you big time. 
 
Mari Norvik, 













Because of an increasing development of antimicrobial resistance, treatment options for 
bacterial infectious diseases are narrowed. A strategy to reduce the evolution of 
resistance is to take advantage of antimicrobial collateral networks. In this thesis, we 
explored these collateral networks with a focus on antimicrobials used in Norway for 
the treatment of cystitis. Cystitis is the most common outcome of urinary tract infection.  
Five clinical strains from a collection of pan-susceptible Escherichia coli (E. coli) isolated 
from uncomplicated urinary tract infection (ECO•SENS) were used. Spontaneous, single 
step mutants selected on trimethoprim, ciprofloxacin and nitrofurantoin were generated 
and their susceptibility determined by E-test. They were confirmed to belong to E. coli 
species by performing random amplified polymorphism DNA polymerase chain reaction 
(RAPD PCR). The susceptibility of the mutants was thereafter tested towards seven 
different antimicrobials. These results were compared to the ancestral strains’ 
susceptibility profiles to the same antimicrobials. This method represented a scenario 
where the susceptibility of an isolate is decreased towards trimethoprim, ciprofloxacin or 
nitrofurantoin due to a spontaneous mutation, but at the same time, the mutants’ 
susceptibility can increase or decrease for a different antimicrobial. The collateral 
networks of mutants with decreased susceptibility to three antimicrobials were 
visualized in heat maps, where blue color displays collateral sensitivity and red color 
indicates drug combinations that show collateral resistance. The use of drug 
combinations that show collateral resistance should be avoided and instead, the use of 
drug combinations that display collateral sensitivity should be applied to hinder the 
increase of antimicrobial resistance. The presented data suggest that acquisition of 
trimethoprim resistance simultaneously increases susceptibility to aminoglycosides and 
mecillinam. Moreover, we provide evidence that the temporal order of antimicrobial 
consumption can be optimized for resistance to trimethoprim and that the use of 
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1.1 State of the art 
Sir Alexander Fleming discovered the first antibiotic in 1928, and it is clear that penicillin 
revolutionized medicine. Without antimicrobials, current treatment options would have 
been much narrower. They enable treatment of patients on an extensive scale. For 
example, performing organ transplantations without antimicrobials would have been 
extremely risky, and it probably would not have been feasible to achieve the current 
survival rates. (Davies and Davies, 2010). 
After 1928, humans have underused, overused and misused antimicrobials to the point 
where resistance to antimicrobials has evolved even further (Davies and Davies, 2010). 
In Europe alone, the death toll from infections due to antimicrobial resistance bacteria is 
25,000 people annually, and the total cost is estimated to be 1.5 billion EUR (ECDC/EMEA, 
2009). Moreover, these numbers are estimated to increase in the future (de Kraker et al., 
2011). It is not only the clinical treatment of humans that leads to the dissemination of 
antimicrobial resistance. In 2010, 13 million kilos of antimicrobials were fed to animals 
in the US to boost their growth rate (Spellberg et al., 2013). Adding to the growing 
problem, pharmaceutical companies are not inventing and developing new antimicrobials 
(Conly, 2005). What can be expected for the future? 
One out of many clinical relevant diseases that can be difficult to treat because of the 
evolution of antimicrobial resistance is urinary tract infection (UTI). Recently an increase 
in resistance to antimicrobials commonly used to treat UTIs has been observed 
(Winstanley et al., 1997, Garau et al., 1999). Uropathogenic bacteria such as E. coli show 
decreased sensitivity to antimicrobials like ampicillin, amoxicillin, sulphonamides, 
trimethoprim and quinolones (Winstanley et al., 1997, Garau et al., 1999). A proposed 
method to deal with the lack of treatment strategies for several bacterial infections is 
renewing antimicrobial stewardship. Already in 1913, Paul Ehrlich discussed 
combination therapy as a strategy to outcompete resistant microbes (Ehrlich, 1913). 
Recent studies support this theory of using drug combinations to surmount antimicrobial 






Antibiotics are produced by microorganisms in order to kill, or inhibit the growth of other 
microorganisms. Since Antimicrobials can be either natural, semisynthetic or synthetic, 
antibiotics are classified as antimicrobials, but antimicrobials are not necessarily 
antibiotics (Goering et al., 2013). 
There are many ways to categorize antimicrobials. When an antimicrobial manages to 
affect both Gram-negative and Gram-positive bacteria, it has a broad spectrum of activity. 
Naturally, an antimicrobial agent with a narrow spectrum of activity affects simply Gram-
negative or Gram-positive bacteria or an even smaller subpopulation. An antimicrobial 
can also be either bactericidal or bacteriostatic. Through a bactericidal effect of an 
antimicrobial, the organism is killed. An organism’s growth can also be inhibited if the 
activity of the antimicrobial is bacteriostatic.  Antimicrobials can also be classified by their 
mechanism of action. There are five main mechanisms based on the inhibited processes: 
cell wall synthesis, membrane function, protein synthesis, nucleic acid synthesis or other 
metabolic processes (Goering et al., 2013). In this thesis, we isolated mutants with 
reduced susceptibility to trimethoprim, ciprofloxacin, and nitrofurantoin, and therefore I 
focus mainly on these antimicrobials throughout the thesis. 
 
1.2.1 Mechanism of action: trimethoprim 
Trimethoprim has primarily a bacteriostatic effect (Felleskatalogen, 2015b). Mammalian, 
bacterial and protozoan cells inherently have the enzyme dihydrofolate reductase 
(DHFR), which is important for folic acid synthesis. By competitive inhibition, 
trimethoprim binds the enzymatic site of DHFR in bacteria. Human cells are resistant to 
trimethoprim. Therefore, trimethoprim can be used clinically with minimal side effects 
(Goering et al., 2013). 
 
1.2.2 Mechanism of action: ciprofloxacin 
Ciprofloxacin has a broad spectrum of activity and a bactericidal effect. It inhibits DNA 
gyrase and topoisomerase II and IV. These enzymes are important for bacterial 






1.2.3 Mechanism of action: nitrofurantoin 
The mechanism action of nitrofurantoin is complex. Intermediates of nitrofurantoin are 
formed through flavoproteins allowing the intermediates to inhibit bacterial ribosomal 
proteins, which prevents protein synthesis, aerobic energy metabolism, DNA, RNA, and 
cell wall synthesis. Nitrofurantoin has a bactericidal effect when treating urinary 
infections and in the presence of acidic urine the antimicrobial effect is increased 
(Felleskatalogen, 2012, UpToDate, 2015a).  
 
1.3 Antimicrobial Resistance 
Antimicrobial resistance is either classified as intrinsic or acquired. Intrinsic resistance is 
species specific, and the result of bacteria naturally encoding for a distinct resistance 
mechanism or lacking the structure or metabolic process of which the antimicrobial is 
targeting. Acquired resistance results from genetic changes to the bacteria that was 
originally sensitive to the antimicrobial. This kind of changes in the bacteria can occur by 
mutations in the bacterial chromosome or following the acquisition of new DNA 
(Hollenbeck and Rice, 2012). 
 
1.3.1 Mechanisms of antimicrobial resistance 
There are three different mechanisms of antimicrobial resistance. The first one prevents 
the antimicrobial from reaching the target either by reducing permeability or increasing 
efflux. The bacteria adapt reduced permeability by downward adjustment or exchanging 
of pores. Efflux is where the bacteria pump the antimicrobial out of the cell. The second 
mechanism of resistance results from changes to the antimicrobial targets by 
spontaneous mutations in the gene that encodes for target molecules. Alternatively, drug 
targets can be modified by, for instance, the addition of a chemical group. The third and 
final mechanism is modification of the antimicrobial. This can happen, for example, by 
hydrolysis of the β-lactam ring by β-lactamase enzymes or by the addition of a chemical 






1.3.2 Genetic variation in bacteria 
Gene transfer mechanisms are clearly involved in the spread of bacterial resistance 
determinants. Gene transfer can be vertical or horizontal. Vertical gene transfer is a linear 
transfer of genes from its ancestor, where it originally evolved, to two daughter cells. 
Horizontal gene transfer is the transfer of genetic material to another cell that is not it’s 
offspring. Moreover, all horizontally acquired genetic changes can then be transferred 
vertically and be maintained in the population (Brown, 2003). 
 
1.3.3 Horizontal gene transfer (HGT) 
Horizontal gene transfer (HGT) is a well-known mechanism of spreading antimicrobial 
resistance. This allows bacteria to exchange DNA either through plasmids carrying 
multiple resistance determinants or bacteriophages. Mechanisms of HGT that are 
understood best are conjugation, transduction and natural transformation (Figure 1). 
Conjugation can take place across the same or various species. The transfer occurs from 
the donor cell to the recipient cell through a pilus as the connector. The plasmid’s origin 
of transfer is pulled through an exporter and into the recipient cell. The plasmid can be 
transferred further through other conjugation events or inherited through cell division. 
Transduction occurs when a bacteriophage transfers DNA between two bacteria. The 
bacterial virus binds to the recipient bacteria and inserts its nucleic acid. In natural 
transformation, a competent recipient cell takes up a fragment of DNA from the 
environment. The DNA fragment that was taken up into the recipient cell has to recombine 
with the recipient chromosome or be stabilized as a plasmid in order to be maintained 







1.3.4 Point mutation 
As reviewed in (Mohammad B. Habibi Najafi, 2013), mutations are changes in the 
deoxyribonucleic acid (DNA) sequence (Figure 1). These changes occur through errors 
during replication or non-repair of DNA damages. Mutations can be either spontaneous 
or induced. The consequence of a mutation can be beneficial, neutral, or harmful to the 
organism. 
A point mutation occurs spontaneously through substitution, deletion or insertion of a 
base. This usually happens during DNA replication. Spontaneous or growth-dependent 
mutations will, in general, occur in 1 out of 106 – 108 cells (Giedraitiene et al., 2011). 
There are three mechanisms of mutations, a substitution of a nucleotide, deletion, or 
addition of a nucleotide. A substitution of a base pair to a different base pair can be divided 
into two categories, transition and transversion. When a transition happens, the base 
substitution occurs with a base from the same chemical category. Alternatively, a 
transversion is when the replacement of a base occurs with a base from a different 
chemical category. Deletion or addition of a nucleotide occurs during DNA replication. 
Point mutations can be silent, missense or nonsense mutations, or cause frameshifts. A 
silent substitution is a change to the amino acid codon that does not alter the amino acid 
sequence. A missense mutation is the change of a codon that originally belonged to 
another amino acid so that it now encodes for a different amino acid. When a codon is 
replaced by a stop codon, it is called a nonsense mutation. Finally, frameshift mutations 
occur when the total nucleotide number changes and the amino acid codons of the 









Figure 1: Illustration of conjugation, transformation, transduction and mutations. 
Adapted from (Andersson and Hughes, 2010).  
 
1.3.4.1 Resistance to ciprofloxacin 
Resistance to fluoroquinolones can occur by changes in the target enzymes, DNA gyrase 
and topoisomerase IV. This affects quinolone binding. A change in bacterial cell wall 
permeability can also arise and result in decreased uptake or increased the efflux of the 
drug through the presence of efflux pumps. 
The target that is most tolerant of mutations will in a chronological order evolve changes. 
In E. coli, mutations occur first in the DNA gyrase enzyme. Further mutations will arise in 
several other genes that are also related to resistance (Jacoby, 2005). When E. coli evolves 
resistance to quinolones, a change in seven or more amino acids in the gyrA gene or three 
amino acids in parC gene are usually responsible (Giedraitiene et al., 2011) The qnr gene 






1.3.4.2 Resistance to trimethoprim 
Susceptible strains can develop acquired resistance to trimethoprim. This is frequently 
caused by a chromosomal mutation that follows the production of DHFR, which may be 
less vulnerable to trimethoprim inhibition. Resistance rarely occurs through plasmids, 
but when it does, a high level of resistance takes place. If transposons transfer from one 
replicon to another resistance can also evolve. A mechanism through efflux pumps is also 
seen in Burkholderia efflux pumps (Podnecky et al., 2015). 
 
1.3.4.3 Resistance to nitrofurantoin 
Resistance to nitrofurantoin develops through stepwise mutations, which occur in the 
nfsA and nfsB genes. These genes encode for oxygen-insensitive nitroreductases. One-step 
mutations occur in the nfsA gene while two-step mutations are found in the nfsB gene. To 
obtain high-level nitrofurantoin resistance, it is necessary to inactivate these two genes 
(Sandegren et al., 2008).  
 
1.3.5 Mutant selection window 
To study how antimicrobial resistance can emerge in nature, microbiologists in the lab 
select for resistant isolates by culturing sensitive bacteria in the presence of the 
antimicrobial of interest. As reviewed in (Courvalin, 2008), an appropriate antimicrobial 
concentration is crucial to obtain mutants. Concentrations should not be as high as the 
mutant prevention concentration (MPC), where it is almost impossible to see any 
bacterial growth. However, they must be higher than the MIC, in order to exclude the 
growth of the wild type (WT). Somewhere between the MPC and MIC, the mutant selection 
window (MSW) exists and this is where spontaneous single step mutations usually occur 
(Figure 2) A new phenomenon termed minimal selective concentration (MSC) suggests 
increased relevance of antimicrobial concentrations below MIC with respect to MSW 







Figure 2: Graph is illustrating how the MSW lies between MIC and MPC. Figure adapted 
from (Michel et al., 2008) 
 
1.4 Antimicrobial susceptibility testing 
The organism of interest’s susceptibility to antimicrobials can be tested in vitro for 
determination of its minimal inhibitory concentration (MIC), and is defined as “ the lowest 
concentration of an antimicrobial that will inhibit the visible growth of a microorganism 
after overnight incubation” (Andrews, 2001). The three most common techniques to 
determine the MIC are the broth dilution method, gradient method (E-test) and disk 
diffusion method. The MIC-value indicates a strain’s susceptibility to the tested 
antimicrobial and the strain can thus be categorized as either “susceptible”, 
“intermediate” or “resistant” (Reller et al., 2009). MIC is also used to determine which 
antimicrobial to use for clinical treatment and to set the appropriate dose regimen 







An increase in MIC indicates a reduced susceptibility. If the MIC has decreased, the 
susceptibility has increased. Clinical breakpoints decide whether the bacterial 
susceptibility change is defined as susceptible, intermediate or resistant. These 
breakpoints are standardized and interpreted by using MIC (µg/mL) or a disk diffusion 
test with the zone of inhibition in diameters (mm) (Turnidge and Paterson, 2007). Clinical 
breakpoints are determined by “dosages, pharmacokinetics, resistance mechanisms, MIC 
distributions, zone diameter distributions pharmacodynamics and epidemiological cut-
off values (ECOFFs)” (EUCAST, 2015). The ECOFF value distinguishes  wild type from non-
wild type (with resistance mechanism) for a given antimicrobial (EUCAST, 2007). 
 
1.4.1 Broth dilution test, antimicrobial gradient method and disk diffusion test  
In the broth dilution test, it is necessary to create a two-fold dilution of antimicrobials. An 
amount of bacteria is incubated in liquid growth medium (2.2.1) at 35 °C for 16-24 hours. 
After incubation, the MIC is determined as the lowest antimicrobial concentration where 
no bacterial growth is visible (Reller et al., 2009).  
The methods on how to use antimicrobial gradient method (E-test) are supplied in 
(3.6,3.7).  
The disk diffusion test utilizes a disk with a set antimicrobial concentration. The disk is 
placed on a pre-streaked LBA plate with the organism of interest and incubated overnight 
at 35 °C. The MIC is interpreted by reading the diameter in millimeters where the bacterial 







1.5 How antimicrobials can work together 
Collateral sensitivity, also known as negative cross-resistance (Kim et al., 2014), is a term 
used for many years and in several contexts. It is mostly spoken of in cancer multidrug 
resistance (Pluchino et al., 2012), but it recently emerged as a hot topic in antimicrobial 
resistance research (Imamovic and Sommer, 2013). 
As Imamovic and Sommer present it; “On the basis of these data, we propose a new 
treatment framework – collateral sensitivity cycling – in which drugs with compatible 
collateral sensitivity profiles are used sequentially to treat infection and select against 
drug resistance development” (Imamovic and Sommer, 2013). The theory proposes that 
when bacteria evolve resistance to one antimicrobial, the sensitivity may be improved to 
another antimicrobial. Collateral sensitivity networks can lead to more efficient killing if 
drugs are used in the same order. This could eliminate resistant bacteria to a greater 
extent as compared to antimicrobials not having this sensitivity network (Imamovic and 
Sommer, 2013).  
It is envisioned that a form of cycling or rotation with two or more antimicrobials can 
delay the evolution of antimicrobial resistance. One criterion is that after ending the 
rotation, the same order of antimicrobials needs to be repeated (Figure 3). On the other 
hand, collateral resistance is a term used when a drug combination evolves a greater 
resistance than expected. This unfortunate outcome is not desired (Kim et al., 2014, 
Pluchino et al., 2012, Imamovic and Sommer, 2013). 
The collateral sensitivity cycling is competition based. It is argued that collateral 
sensitivity will lead to a competitive replacement if two antimicrobials with reciprocal 
collateral sensitivity are cycled. This competition between the two resistant and 
susceptible strains are based on the idea that susceptibility to the next drug to be higher 
in the accumulated resistant (previous drug) strain than in the WT. Consequently, cycling 











Figure 3: This illustration shows how collateral sensitivity networks can eradicate 
antimicrobial resistance. When treating a susceptible pathogen with Drug A for a while, 
resistance will develop (blue pathogens, t1). When switching to Drug B an eradication of 
resistant bacteria from Drug A will take place (t2). After treating with Drug B, the pathogen 
will become resistant (t3) and a switch back to Drug A is necessary to outcompete 







There are two different ways of combining antimicrobials. The alternating method is 
described as periodic switching between antimicrobials (as above). The second way is to 
combine antimicrobials as a multidrug, usually consisting of two antimicrobials, called 
“combination therapy” (Kim et al., 2014). 
As reviewed in (Bell, 2005), antimicrobials can cooperate by inhibiting resistant bacteria 
in a more effective way. Drugs possessing this capacity have a “synergistic” quality. 
Conversely, a drug combination can also carry out an “antagonistic” effect, by killing fewer 




Figure 4: Difference between drug additivity, synergy and antagonism. Adapted from 







1.6 Organism of interest 
E. coli is a mammalian, intestinal, Gram-negative bacterium, which the German 
pediatrician, Theodor Escherich, described for the first time in 1885 (Escherich, 1885). E. 
coli is a member of the family Enterobacteriaceae (Starr, 1986). A Short time after birth, 
E. coli is present in the human intestine. In a few cases, E. coli can be pathogenic and cause 
disease. When E. coli travel from their source to another area of the body, E. coli can often 
outcompete resident members of the normal flora and cause disease. The most common 
diseases caused by E. coli are diarrhea, UTIs and meningitis (Kaper et al., 2004).  
 
1.6.1 ECO•SENS isolates 
The ECO•SENS I and II studies mapped the susceptibility profiles of uropathogenic E. coli 
isolates originating from uncomplicated UTIs in women and included samples from 16 
European countries and Canada. Identified isolates were susceptibility tested against 
antimicrobials commonly used for the treatment of UTIs. The time difference between the 
two studies, ECO•SENS I and II, was twelve years. The authors tested how the 
susceptibility had evolved between study I and II and found there were increases of 
resistance to nalidixic acid (4.3% to 10.2%) ciprofloxacin (1.1% to 3.9%) and 
trimethoprim (13.3% to 16.7%) (Kahlmeter, 2000, Kahlmeter and Poulsen, 2012). In this 
thesis, we work on several isolates from this strain collection that are “pan-susceptible” 








As many as 150 million incidents of urinary tract infection occur worldwide each year. 
The estimated financial costs are in the range of 6 billion dollars. E. coli is present in 70-
95% of community-acquired UTIs (Kucheria et al., 2005). UTI is a collective term for 
cystitis, pyelonephritis and asymptomatic bacteriuria. Cystitis can be complicated or 
uncomplicated. An uncomplicated cystitis affects healthy, non-pregnant women and is the 
most frequent form of UTI. Complicated cystitis is caused by anatomic conditions often 
affecting pregnant women, men, children and elderly (Helsedirektoratet, 2012). 25-30% 
of all women with uncomplicated cystitis will have recurrences of cystitis. Uncomplicated 
cystitis causes significant morbidity especially when recurring (Kucheria et al., 2005). 
Treatment options for uncomplicated cystitis are narrowed because of antimicrobial 
resistance development (Grigoryan et al., 2014).  
The current Norwegian guidelines for treatment of uncomplicated cystitis (Figure 5) 
include trimethoprim, nitrofurantoin and mecillinam as a first choice and ciprofloxacin as 
a backup if resistance has developed. The guidelines are similar to the treatment of 
complicated UTI except ciprofloxacin can also be used as a second choice treatment, 













The aim of this study is to investigate networks of collateral resistance and collateral 
sensitivity in clinical E. coli strains with pre-existing resistance determinants relevant for 
the treatment of UTIs. 
We hypothesize that collateral sensitivity and collateral resistance networks for certain 
drugs display general patterns in clinical strain collections and that this information can 
provide a basis for novel evidence-based treatment guidelines that reduce the evolution 













In addition, Sambrook, Russell, Molecular Cloning - A laboratory manual, 2001 was used 
for materials and methods. 
 
2.1 Bacterial strains 
The bacterial strains used in this work are listed in Table 1. This is a collection of pan-
susceptible E. coli clinical isolates, which were isolated from UTIs. 
 
Table 1: E. coli isolates used in this study. 
Name Sero Type Phylogroup Country Year 
K56-2  ST73 B2 Greece 2000 
K56-75  ST69 D UK 2007-08 
K56-68  ST95 B2 Sweden 2007-08 
K56-16  ST127 B2 Portugal 2000 
K56-44  ST12 B2 Greece 2007-08 
 
2.2 Growth media 
 
2.2.1 Luria Bertani (liquid) medium (LB medium) – 200 mL 
In order to be able to do multiple experiments, a growth media was needed for the 
bacteria. Luria Broth (LB) is a nutrient often used to culture bacteria. The solution 
consisted of 5 g DifcoTM Luria Broth, Miller (USA) powder and 200 mL distillated water 
(dH2O). One liter LB medium consisted of 10 g tryptone, 5 g yeast extract and 10 g sodium 
chloride. The pH was measured at 7 with a TriTest (Mecherey – Nagel, Germany). A pH 
adjustment was therefore not needed. The LB media was autoclaved for 20 minutes at 






2.2.2 Luria Broth and Agar (LBA) – 40 plates 
To make LB agar plates, agar was added to stiffen the solution. For making 40 dishes of 
LBA, 20 g of LB-broth and 12 g Select agar (Sigma-Aldrich, Germany) were mixed with 
800 mL distilled water. The solution was autoclaved for 20 minutes at 121 °C. Following 
autoclaving, the mixture was cooled to 55 °C and poured into polystyrene petri dishes 
(VWR International, 90x16.2mm) (Addgene, 2014). 
 
2.2.3 Mueller-Hinton Agar 2 (MHA2) – 40 plates 
These plates were used for almost all E-tests. 38 g Mueller Hinton Agar 2 (Sigma-Aldrich, 
Switzerland) per liter ddH2O was boiled for 1 minute and autoclaved at 121°C for 15 
minutes and cooled to 50°C and poured into polystyrene petri dishes (VWR International, 
90x16.2mm). 
 
2.3 Antimicrobial stock solutions  
 
2.3.1 Trimethoprim: 
A stock solution (provided by Nils Hülter) at a final concentration of 100 mg/mL was used. 
The plates were made at concentrations of 3 µg/mL and 4 µg/mL trimethoprim. The 
volume of the bottle with LB Agar was 800 mL. 
 
2.3.2 Ciprofloxacin: 
To make a ciprofloxacin stock of 10 mg/mL, 100 mg ciprofloxacin ≥ 98% (HPLC, Fluka, 
China) was dissolved in 10 mL of distilled water. The ciprofloxacin dissolved with the 
addition of 10 drops of 3.7% HCl. The solution was sterile filtrated with a syringe and 
syringe filters (Acrodisc®, 25 mm) The LBA ciprofloxacin petri dishes were made at a 








The final concentration of the nitrofurantoin stock solution was 40 µg/mL. 4 g 
Nitrofurantoin (crystalline, Sigma-Aldrich, Germany) was dissolved in 100 mL DMSO. The 
plates contained nitrofurantoin at a concentration of 6 µg/mL and 12 µg/mL (= 2×MIC). 
The MIC was 3 µg/mL and 6 µg/mL (Sandegren et al., 2008). 
Of the 800 mL liquid LB medium (not yet autoclaved and the agar was not added yet), 20 
mL were taken out, and 240 µL of the 40 µg/mL nitrofurantoin stock solution were added. 
12 g agar powder was added to the remaining liquid LB and the media was autoclaved. 
The liquid LB containing nitrofurantoin was sterile filtered. After autoclavation, the 
solution with nitrofurantoin was added when the agar solution reached a temperature of 






2.4 Buffer, reagents and other solutions  
50% glycerol solution: For making 100 mL 50% glycerol solution, 57.5 mL 86-89% 
glycerol (Sigma-Aldrich, Germany) solution were mixed with 42.5 mL distilled water. 
The solution was autoclaved for 20 minutes at 121 °C. 
 
0.9% NaCl : 9 g NaCl (Sigma-Aldrich, Germany) were dissolved in 1 L distilled water. The 
solution was autoclaved for 20 minutes at 121 °C. 
 
TAE buffer (50X): TAE (Tris-acetate and EDTA) buffer was used for gel electrophoresis. 
For making 1 liter of the buffer, 242 g Trizma® Base (Sigma-Aldrich, Germany) was 
dissolved in 800 mL of distilled water. Additionally, 57.1 mL glacial acetic acid (Merck, 
Germany) and 100 mL of 0.5 M EDTA (GIBCO® Invitrogen) pH 8.0 were added. The 
volume was then brought up to 1 L with distilled water. The buffer was diluted to a 
concentration of 1×TAE before use. 
 
Gel- loading buffer (6X): 0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol 
in water + 6 mM EDTA, pH 8.  
 
Smart ladder: Eurogentec, 200-10,000 bp, 5 µl/lane. 
 
Mastermix: DreamTaq PCR master mix (2x) (Thermo Scientific, Germany), DreamTaq 
DNA Polymerase, optimized DreamTaq, MgCl2, and dNTPs. 
 
Primers: M13 primer for RAPD – PCR analysis, 5 µM working solution. With the 
sequence: 5’ – GAGGGTGGCGGTTCT – 3’ 
 









3.1 Overnight culture 
For inoculation of an overnight culture, a single colony was taken from the bacterial 
isolate and resuspended in 30 mL of liquid LB medium. Cultures were incubated at 37°C 
with shaking at 150 rotations per minute (rpm) for 12-18 hours. The total volume of the 
overnight culture was distributed in three sterile falcon tubes. The tubes were centrifuged 
at 4000 rpm for 10 minutes, forming a pellet. The pellet was resuspended in 1 mL of fresh 
liquid LB medium (Addgene). 
 
3.2 Generation of spontaneous mutants 
To obtain mutants with reduced susceptibility to trimethoprim, ciprofloxacin and 
nitrofurantoin individually, the E. coli strains of interest were plated on LBA with varying 
concentrations of the antimicrobial.  
100 µL (109 cells) overnight culture (see above) was plated using sterile glass beads onto 
a pre-dried LBA plate, containing the appropriate antimicrobial. Plates were incubated at 
37°C for 12-18 hours. Single isolated colonies were chosen and struck for isolation on a 
new petri dish containing the same antimicrobial concentration to confirm re-growth. 
Possible mutant colonies were further characterized by confirmation using PCR (3.4) and 
antimicrobial susceptibility testing (3.6). 
 
3.3 Freeze stock culture 
Bacterial strains were stored at -80 °C. To prepare the samples, 1.8 mL Falcon freeze tubes 
(VWR International, USA) were filled with 500 µL LB and 500 µL 50% glycerol. A sterile 







3.4 Polymerase Chain Reaction (PCR) 
A PCR is a reaction where specific portions of DNA are amplified by polymerases. 
It switches between different temperatures at different times Table 2. 
During the first and second step, double-stranded DNA (dsDNA) denatures to single-
stranded DNA (ssDNA). In the third step, the primer binds to complementary segments of 
the ssDNA. DNA polymerase builds the new dsDNA strand, in the fourth step, using the 
complementary ssDNA as a template. Afterward, steps 2-4 are repeated 45 times.  
The PCR technique applied in this project is called random amplified polymorphism DNA 
(RAPD) analysis Table 2. 
This process comprises of the “PCR amplification of random fragments of genomic DNA 
with an arbitrary sequence (Maslow et al., 1993). This method does not require 
information about the DNA sequence (NCBI, 2015). The primer used in this technique is 
called M13. M13 is a single primer that binds to arbitrary sequences.  
Mutant samples, a positive control and negative controls, (Acinetobacter) and water, were 
prepared for PCR. From the colonies that re-grew on selective media, a single colony was 
once more picked, but this time was plated on an LBA plate for DNA extraction. The test 
samples were compared with the positive E. coli control. A negative control was included 
to compare against the positive. Bacterial colonies or isolated DNA (test samples, positive 
and negative controls) were resuspended in 100 µL double distilled water (ddH2O). The 
samples were boiled for 10 minutes and then centrifuged at 13,000 rpm for 10 minutes. 
The supernatant was used as the PCR template. Each PCR-tube contained DreamTaq 
mastermix, M13 primer, ddH2O and template (Table 3). All of the preparations were done 








Table 2: RAPD PCR program used in this thesis. The temperature and duration for each 
step are showed. 
Step Temperature Time 
1 95 ˚C 5 min 
2 95 ˚C 1 min 
3 36 ˚C 1 min 
4 72 ˚C 2 min 
5 Repeat 2-4 45 times 
6 4 ˚C ∞ 
 
 
Table 3: Proportion of ingredients used for the PCR 
Reagent Volume 
Mastermix 15 µL 
M13 primer 5 µL 
dd H2O 3 µL 
Template 2 µL 










3.5 Agarose gel electrophoresis 
Gel electrophoresis separates DNA according to size. The flow of electricity, 
electrophoresis, moves a negatively charged DNA molecule towards a positive electrode. 
The shortest DNA fragments migrate the fastest. The mutant samples were compared to 
the length of the bands of the positive control. Using this technique, the samples were 
identified as either a desired E. coli mutant or a contaminant. The first step was to make 
the agarose gel. The concentration of the agarose gel was 2%, for the best separation of 
the bands. 2 g of agarose (SeaKem® LE Agarose, USA) were dissolved in 100 mL of 1×TAE 
buffer. The solution was put in the microwave oven for 1-3 minutes. After 5 minutes of 
cooling, 20 µL ethidium bromide (stock solution: 1 mg/mL) was added to the liquid 
agarose solution. Then the agarose solution was poured into the gel casting tray and left 
to stiffen (20-30 minutes). 2 µL loading buffer were added to 10 µL of the RAPD-PCR 
samples. When the agarose gel was put in the electrophoresis chamber, it was filled with 
1×TAE buffer so that all of the gel was covered. 10 µL smart ladder was loaded into the 
first and the last lane and 10 µL of each sample was loaded in the lanes between the 
ladders. Then the gel was run at 90 volts for approximately 1 hour. Finally, the DNA 
fragments were visualized and analyzed under UV light (Addgene). The patterns of the 
amplified segments from the gel were interpreted by comparing the test samples bands 
with the bands of the positive control.  
 
3.6 Antimicrobial susceptibility testing: E-test 
An E-test is a premade strip of an antimicrobial with a gradient concentration. The MIC is 
read at the point where the growth stops. Trimethoprim and tetracycline are 
bacteriostatic antimicrobials, and the inhibition zone needs, therefore, to be read at 80% 
inhibition of growth. The other antimicrobials are bactericidal and the MICs were read at 
100% inhibition (Table 4) (AbBiodisk, 2007). A bacterial suspension adjusted to 0.5 
McFarland (turbidity standard for bacterial suspensions) was prepared and spread on a 
LBA/MHA2 dish with a sterile cotton tip in three different directions. The E-test was 
placed in the middle of the dish with sterile tweezers. The petri dish was incubated at 







Table 4: Antimicrobials and their properties (UpToDate, 2015b). 
Antimicrobial 
name 




Used for treating 
UTI: 
Trimethoprim TRI Folic acid 
biosynthesis 
Bacteriostatic Yes 
Ciprofloxacin CIP Gyrase Bactericidal Yes 
Nitrofurantoin NIT Multiple 
mechanisms 
Bactericidal Yes 
Gentamicin GEN Protein synthesis Bactericidal Yes 
Kanamycin KAN Protein synthesis Bactericidal Yes 
Tetracycline TET Protein synthesis Bacteriostatic No 
Colistin COL Lipopolysaccharide Bactericidal No 
Mecillinam MEC Cell wall Bactericidal Yes 
 
 
3.7 MIC testing with E-tests 
After all of the mutants were harvested and stored at -80°C, the main experiment was up 
next. In the last section, testing with different antimicrobial E-tests was going to be carried 
out. The mutants were tested against seven different antimicrobials: gentamycin, 
kanamycin, tetracycline, colistin, mecillinam and nitrofurantoin, ciprofloxacin or 
trimethoprim (Table 4). To determine if there was a significant difference between the 
WT MIC and the mutants’ final concentration, the E-test values needed to be read in a 
specific way. First, the concentration where the bacteria stopped growing was noted 
down. Second, if the basis value was between a two-fold-dilution, the result was rounded 
up to the nearest two-fold concentration. Third, the result was significant if there was a 
two-fold-dilution difference between the values being compared (this was done for all E-
tests). The results were visualized in a heat map. Double mutants provided from an 
ongoing project were added to the experiment. A double mutant consisted of an isolate 








In this thesis, spontaneous mutants with reduced susceptibilities to trimethoprim, 
ciprofloxacin, and nitrofurantoin were isolated by selection on the respective 
antimicrobial agent. Three double mutants with reduced susceptibility to both 
trimethoprim and ciprofloxacin were provided from an ongoing laboratory project. 
Selected representative mutants were verified by E-tests and RAPD-PCR and frozen down 
for further analyzes. Several strains displayed variable abilities to form mutants with 
reduced susceptibilities to the drugs applied here. This may be a reflection of intrinsic 
differences between the clinical strains. In some cases, the MIC value varied for the 
mutations that originated from the same strain. When this occurred, more mutants from 
that strain were selected for further MIC testing. The susceptibility profiles of mutants 
with reduced susceptibility to one or two antimicrobials were determined for seven 
different antimicrobials and heat maps were constructed, as presented in (Imamovic and 
Sommer, 2013). In these heat maps, blue color indicates increased susceptibility 
(collateral sensitivity) and red indicates a decreased susceptibility (collateral resistance). 
The different shades of each color display the fold susceptibility increase or decrease 
compared to the WT for each of the antimicrobials. A 32-fold increase/decrease has the 
darkest shades and the 2-fold increase/decrease has the lightest shades. 
In general, single and double mutants of ciprofloxacin and trimethoprim tend to show 
increased MICs to both colistin and nitrofurantoin. The MIC increased as well when the 












4.1 Mutant generation and confirmation 
A total of 76 mutants were collected with reduced susceptibilities to trimethoprim, 
ciprofloxacin and nitrofurantoin. Of those 76 isolates, 39 were selected on trimethoprim, 
36 on ciprofloxacin, and 1 was found on nitrofurantoin. Altogether, 66 mutants were 
confirmed by RAPD-PCR and E-tests. The 10 remaining mutants could not be confirmed 
due to lack of DNA bands in the agarose gel electrophoresis picture. When the gel did not 
confirm the mutant as E. coli, an E-test was not performed (Table 5).  
It was possible to obtain only one mutant from the selection on nitrofurantoin. The 
ancestral strain was K56-2, and it was given the isolate name 2.3 NIT. The concentration 
of the nitrofurantoin plates used for selection were double the MIC of the ancestral strains. 
Since MIC WT was 8 µg/mL, the plates had a concentration at 16 µg/mL. The MIC of the 
resulting mutant was 16 µg/mL. The final MIC susceptibility testing results can be seen in 
Table 11 and Table 18. 
The trimethoprim mutants were generated at three different drug concentrations, 3 and 
4 µg/mL (Table 14). When the MIC was tested for the WT, most of the strains had a MIC 
of 1 µg/mL, but strain K56-75 had a value as low as 0.25 µg/mL. The 75.3 mutant had a 
MIC of 32 µg/mL, which was the same for most of the mutants, except for 44.8. Isolate 
44.8 had a MIC of 2 µg/mL, which indicates only a 2-fold decrease in susceptibility. The 
mutant with the highest change in susceptibility was 75.3, with a 128-fold change 
 (Table 6).  
Ciprofloxacin selection occurred at only one plate concentration, 0.1 µg/mL (Table 15). 
All of the WT strains had a MIC of 0.008 µg/mL, and the MIC of the mutants were either 
0.25 or 0.5 µg/mL. The susceptibility decreased, therefore, by 31 or 63 fold (Table 7).  
The ancestral MICs are listed in Table 8. The antimicrobials that had the greatest 
variation of MIC between the selected mutants and the WTs are mecillinam, 
trimethoprim, and gentamycin. A total MIC difference of 4 fold can be seen for the 








Table 5: Numbers of spontaneous E. coli mutants isolated on different selective plates. 
Strain Total isolates Confirmed Unconfirmed 
 TRI CIP NIT TRI CIP NIT TRI CIP NIT 
K56-2 4 8 1 4 8 1 0 0 0 
K56-16 12 13 0 12 9 0 0 4 0 
K56-44 7 7 0 7 7 0 0 0 0 
K56-68 5 4 0 2 2 0 3 2 0 
K56-75 11 4 0 11 3 0 0 1 0 
Total 39 36 1 36 29 1 3 7 0 
Abbreviations: TRI – trimethoprim; CIP – ciprofloxacin; NIT – nitrofurantoin. 
  
 
Table 6: Trimethoprim mutants used in the thesis with decreased susceptibility. 
 Trimethoprim Concentration (µg/mL)  
Mutant Selection WT MIC MIC mutant Fold Change 
2.1 TRI 4 1 ≥ 32 ≥ 32 
16.5 TRI 4 1 ≥ 32 ≥ 32 
44.7 TRI 4 1 ≥ 32 ≥ 32 
44.8 TRI 4 1 2 2 
44.14 TRI 4 1 16 16 
68.13 TRI 4 0.5 ≥ 32 ≥ 64 
75.3 TRI 3 0.25 ≥ 32 ≥ 128 











Table 7: Ciprofloxacin mutants used in the thesis with decreased susceptibility. 
 Ciprofloxacin Concentration (µg/mL)  
Mutant Selection MIC WT MIC Mutant Fold change 
2.3 CIP 0.1 0.008 0.5 63 
2.5 CIP 0.1 0.008 0.5 63 
2.7 CIP 0.1 0.008 0.25 31 
16.1 CIP 0.1 0.008 0.25 31 
16.3 CIP 0.1 0.008 0.25 31 
16.11 CIP 0.1 0.008 0.5 63 
44.4 CIP 0.1 0.008 0.5 63 
44.5 CIP 0.1 0.008 0.5 63 
68.1 CIP 0.1 0.008 0.5 63 
75.1 CIP 0.1 0.008 0.25 31 
Abbreviations: CIP – ciprofloxacin 
 
 
Table 8: Antimicrobial susceptibility testing of WT E. coli strains used in this thesis. 
 
Strain 
Minimal inhibitory concentration (µg/mL)  
GEN KAN TET COL NIT MEC TRI CIP 
K56-2 1 4 4 1 8 0.25 1 0.008 
K56-16 2 4 4 1 4 0.25 1 0.008 
K56-44 2 8 2 0.5 8 1 1 0.008 
K56-68 4 8 2 1 8 0.5 0.5 0.008 
K56-75 2 8 2 0.5 4 0.25 0.25 0.008 
Abbreviations: GEN – Gentamycin, KAN – Kanamycin, TET – Tetracycline, COL – Colistin, 







4.2 RAPD-PCR and agarose gel electrophoresis 
As shown in (Table 5) not all of the mutants were confirmed as E. coli by agarose gel 
electrophoresis because of a lack of bands. When DNA bands were displayed as showed 
in Figure 6, E. coli had bands at ≈ 400 and 700 base pairs (bp) and at 1.5 and 2 kilo base 
pairs (kbp).  
Figure 6 shows an example of a gel picture. The positive control did not have as bright 
bands as the rest of the samples, and missed a band at 2 kbp as in numbers 2-8. A band at 
1.5 kbp was present in the positive control, 2, 5, 6, and water. Bands at 700-800 bp were 
present in 1-8, water, and positive control.  
Samples 1-8 display similar patterns as observed in the positive control. The results 
support that the isolated mutants with reduced susceptibility to ciprofloxacin originate 
from the WT E. coli ECO•SENS strain K56-44. 
  
Figure 6: Agarose gel electrophoresis result of K56-44 ciprofloxacin mutants. Number 4 






4.3 Collateral-sensitivity and –resistance networks 
 
4.3.1 Trimethoprim 
In Table 14 total generated trimethoprim mutants are displayed. Seven trimethoprim 
mutants were chosen for a closer look at putative collateral networks. Three were 
originating from the K56-44 strain since the MIC of the mutants varied greatly within the 
same strain (2-32 µg/mL). For the remaining strains, only one mutant was used because 
the MIC values of the mutants were more consistent. Trimethoprim resistance is defined 
by a MIC above the clinical breakpoint of 4 µg/mL, while sensitivity is defined as a MIC at 
or below 2 µg/mL Of the mutants tested, 6 had MICs above the clinical breakpoint for 
resistance. Mutant 44.8 is defined as sensitive because the MIC is 2 µg/mL, but the mutant 
is still less susceptible to trimethoprim than the WT (1 µg/mL) (Table 9).  
 
MIC testing was used to determine the susceptibility of these trimethoprim mutants to 
kanamycin and mecillinam compared to the WT strain. For these antimicrobials, there 
was a 4-8 fold decrease in MIC of the mutants compared to the WT. This means that the 
acquisition of trimethoprim resistance led simultaneously to increased susceptibility to 
kanamycin and mecillinam. In the case of gentamicin and tetracycline, there were 2-8 fold 
reductions in MIC. No change in the MIC was observed when trimethoprim mutants were 
tested to ciprofloxacin. Some of the trimethoprim mutants also had no change in 
susceptibility to colistin and nitrofurantoin (Table 9). 
 
A few of the genetic backgrounds of the trimethoprim mutants displayed increased MICs 
when tested to nitrofurantoin and colistin compared to the WT when tested to these 
antimicrobials. This indicates that some of the trimethoprim mutants have a decreased 
susceptibility to nitrofurantoin and colistin compared to the WT’s susceptibility to those 
antimicrobials (Table 9).  







Table 9: Fold change in MIC values for trimethoprim-selected mutants compared to the WT. The ECOFF value is 0.064 -2µg/mL, and 
clinical breakpoints are defined as S < 2, R > 4. The heat map is an inspiration from (Imamovic and Sommer, 2013). 
Strain Mutant nr MIC WT MIC mut. GEN  KAN  TET COL NIT MEC CIP 
K56-2 2.1 TRI 1 32 
              
K56-16 16.5 TRI 1 32 
              
K56-44 44.7 TRI 1 32 
              
K56-44 44.8 TRI 1 2 
              
K56-44 44.14 TRI 1 16 
              
K56-68 68.13 TRI 0.5 32 
              
K56-75 75.3 TRI 0.25 32 
              
 
 
- >32 - 16 - 8 -4 - 2 0 + 2 + 4 + 8 + 16 + >32 
 
 






In Table 15 the total generated ciprofloxacin mutants are displayed. The ciprofloxacin 
mutants used for examinating collateral networks are shown in Table 10. A total of 10 
mutants were used. The mutants were chosen based on how much the MIC varied within 
the same strain. Three isolates from the K56-2 strain (MIC = 0.25-0.5 µg/mL), 3 from K56-
16 (0.19-0.5 µg/mL), 2 from K56-44 (0.38-0.5 µg/mL) and 1 each from K56-68 and K56-
75 were selected for further testing.  
Ciprofloxacin resistance is defined by having a MIC above the clinical breakpoint of 1 
µg/mL, while sensitivity is defined as 0.5 µg/mL or below. All of the mutants are defined 
as sensitive, but still the susceptibility is lowered compared to the WT.  
The mutants with reduced susceptibility to ciprofloxacin were subjected to MIC testing 
using antimicrobial as in Table 10. Strikingly, a near universal pattern of collateral 
sensitivity to gentamicin, kanamycin, tetracycline, mecillinam and collateral resistance to 
nitrofurantoin and colistin, as demonstrated for the trimethoprim mutants, was also 
observed in the mutants with reduced susceptibility to ciprofloxacin (Table 10). 











Table 10: Fold change in MIC values for ciprofloxacin-selected mutants compared to the WT. The ECOFF value is 0.004-0.064 and the 
clinical breakpoints are defined as S ≤ 0.5, R > 1. The heat map is an inspiration from (Imamovic and Sommer, 2013). 
Strain Mutant Nr MIC WT MIC mut. GEN KAN TET COL NIT MEC TRI 
K56-2 2.3 CIP 0.008 0.5        
K56-2 2.5 CIP 0.008 0.5        
K56-2 2.7 CIP 0.008 0.25        
K56-16 16.1 CIP 0.008 0.25        
K56-16 16.3 CIP 0.008 0.25        
K56-16 16.11 CIP 0.008 0.5        
K56-44 44.4 CIP 0.008 0.5        
K56-44 44.5 CIP 0.008 0.5        
K56-68 68.1 CIP 0.008 0.5        
K56-75 75.1 CIP 0.008 0.25        
 
- >32 - 16 - 8 -4 - 2 0 + 2 + 4 + 8 + 16 + >32 






Only one nitrofurantoin mutant was available for testing collateral networks Table 11. 
This mutant originated from the K56-2 strain. 
Nitrofurantoin resistance is defined by having a MIC about the clinical breakpoint of 64 
µg/mL, while sensitivity is defined as a MIC of 64 µg/mL or below. The mutant is therefore 
not resistant, but the mutant is still less sensitive to nitrofurantoin than the WT 
(Table 11). 
The mutant with reduced susceptibility to nitrofurantoin was subjected to MIC testing 
using the same antimicrobial agents as in Table 11. For this nitrofurantoin mutant it was 
observed collateral sensitivity to gentamicin, kanamycin, and tetracycline, as was present 
in the trimethoprim and ciprofloxacin mutants. The mutant also displayed a collateral 
sensitivity towards trimethoprim (Table 11). 
The nitrofurantoin mutant showed a two-fold increase in MIC when tested to colistin, 
mecillinam, and ciprofloxacin compared to the WT MIC when tested to these same 
antimicrobials. This indicates that the nitrofurantoin mutant has a decreased 
susceptibility to colistin, mecillinam, and ciprofloxacin compared to the WT (Table 11). 












Table 11: Fold change in MIC values for nitrofurantoin-selected mutants compared to the WT. The ECOFF value is 4-64 µg/mL and the 
clinical breakpoints are defined as S ≥ 64 < R. The heat map is an inspiration from (Imamovic and Sommer, 2013). 




GEN KAN TET COL TRI MEC CIP 
K56-2 
ST73 
NIT2.3 6 16 
              
 
 





4.3.4 Double mutants 
The double mutants used for the collateral network assay are listed in Table 12. A total 
of 3 mutants were used, one double mutant from each of the K56-2, K56-68 and K56-75 
strains. All of these mutants had MICs above 4 µg/mL for trimethoprim and are defined 
as resistant. However for ciprofloxacin the mutants had a MIC below 1 µg/mL, which 
indicates that they are not resistant, but they are still less susceptible than the WT.  
Interestingly, the double mutants with reduced sensitivity to both trimethoprim and 
ciprofloxacin tend displayed collateral sensitivity and resistance network similar to the 
trimethoprim and ciprofloxacin single mutants (Table 13). 
The MIC values based on the heat map is shown in appendix Table 19. 
 





Table 12: Overview of the MIC for the strains and mutants and clinical breakpoints and 
ECOFF value.  





















0.25 0.008 32 0.5 
 
Abbreviations: TRI – trimethoprim, CIP – ciprofloxacin. 
1 – Clinical breakpoints for trimethoprim (S ≤ 2, R > 4), ECOFF values 0.064 – 2 
2 – Clinical breakpoints for ciprofloxacin (S ≤ 0.5, R > 1), ECOFF values 0.004 – 0.064 
 
Table 13: Fold change in MIC values for double-selected mutants compared to the WT. 
The heat map is an inspiration from (Imamovic and Sommer, 2013). 
Strain Double 
Mutant nr 
GEN KAN TET COL NIT MEC 
K56-2  2.1 TRICIP 
 
           
K56-68  68.1 TRICIP 
 
            
K56-75  75.1 TRICIP 
 
            
 
 








In the recent years, antimicrobial resistance has developed, bringing along increased 
fatality rates than earlier. If this problem continues to increase and is not controlled, the 
risk of not having any options for the treatment of a bacterial infection is a future possible 
scenario (ECDC/EMEA, 2009).  
In this thesis, a possible way of solving this increasing problem is investigated. The basis 
of this project is a procedure in which antimicrobials are alternated according to 
increased susceptibility of otherwise resistant strains, a phenomenon, which is based on 
a so-called collateral sensitivity effect (Imamovic and Sommer, 2013) 
Five clinical strains from the ECO•SENS study (Kahlmeter, 2000) were used to generate 
mutants with decreased susceptibility to trimethoprim, ciprofloxacin and nitrofurantoin 
under selective pressure (plating on antimicrobial containing medium). Double mutants 
were also generated, combining trimethoprim and ciprofloxacin resistance in the same 
genetic background (representing multi-drug resistance). The results of MIC 
determination were presented in heat maps inspired by (Imamovic and Sommer, 2013). 
These heat maps indicated that mutants of trimethoprim and ciprofloxacin, both single 
and double mutants, tend to display collateral increased sensitivity to kanamycin, 
gentamycin, tetracycline, mecillinam, trimethoprim, and ciprofloxacin. On the other hand, 
the same mutants tend to display collateral reduced susceptibility to colistin and 
nitrofurantoin. The nitrofurantoin mutant displayed collateral increased sensitivity to 
kanamycin, gentamycin, tetracycline, and trimethoprim and collateral reduced sensitivity 
to ciprofloxacin and mecillinam and colistin. It will be interesting to see if these results 









5.1 Collateral networks 
 
5.1.1 What do the results tell us? 
The findings presented in this thesis, if underscored by additional work in vitro and in vivo 
can suggest a change to the national and international guidelines of treating UTIs. Today 
the Norwegian guidelines for treating uncomplicated UTIs include trimethoprim, 
nitrofurantoin, and mecillinam as the agents of first choice and ciprofloxacin as a backup 
agent if resistance has developed indicated by treatment failure or susceptibility testing. 
The guidelines are similar for treating complicated UTIs, with the only difference that 
ciprofloxacin can also be used as a second choice treatment, regardless of resistance 
(Helsedirektoratet, 2012) Figure 5. 
In full awareness that the presented results are preliminary, a possible procedure for 
alternating antimicrobials is suggested (Figure 7). This sequential “combination-
treatments” will, following resistance development to first line treatments (Figure 7, left 
panel), ultimately lead to increased treatment efficacy and possibly reduced rates of 
resistance evolution. The results of this thesis may also suggest which antimicrobials 
should not be used in a two-way alternation of antimicrobials (Figure 8). The pattern of 
the results in this thesis may also look like it is beneficial to exercise extra caution when 
using nitrofurantoin either as the first or second line drug. Figure 7 and 8 displays result-
tendencies of the isolates from the heat maps (Table 9, Table 10 and Table 11), not all 
of the isolates show similar collateral networks. For example, three out of seven 
trimethoprim mutants exhibited collateral resistance towards nitrofurantoin, where the 
















Figure 7: Illustrates tendencies of collateral sensitivity networks in antimicrobials used 
treating uncomplicated cystitis. This displays possible procedure for alternating 
antimicrobials. The circles to the left are generated mutants from different antimicrobials 
and the circles to the right displays what antimicrobial the mutants tend to have collateral 
sensitivity towards. Based on heat maps (Table 9, Table 10, Table 11). Adapted and 









Figure 8: Illustrates tendencies of collateral resistance networks for antimicrobials used 
treating uncomplicated cystitis. The circles to the left are generated mutants from 
different antimicrobials and the circles to the right displays what antimicrobial the 
mutants tend to have collateral resistance networks towards. Based on heat maps  
(Table 9, Table 10, Table 11). Adapted and modified (Imamovic and Sommer, 2013). 
 
Gentamycin and kanamycin can be used for treating UTIs, but tetracycline and colistin are 
not used for this indication. Tetracycline and colistin were included in this thesis to show 
that guidelines for a variety of diseases treated with antimicrobials are necessary to avoid 
collateral resistance development. 
The double mutants used in this thesis exhibited reduced susceptibility to multiple drugs 
similar to what was demonstrated for single mutants of trimethoprim and ciprofloxacin. 
Surprisingly, this suggests that the acquisition of two determinants with decreased 
susceptibility does not seem to affect the collateral sensitivity profiles in E. coli. This needs 
further exploration and investigations on the effects of mobile genetic elements should 
also be included. If such general patterns exist, it is promising for the future applications 
of these and similar findings as collateral sensitivity based guidelines can be applied to 





The collateral networks demonstrated here lay within the range of +/- 8-fold 
susceptibility change. The isolates generated from the selection on the same 
antimicrobial, tend to show generally similar results for the different antimicrobial 
susceptibility testing. Though some showed different fold collateral sensitivity, others 
displayed, for example, collateral resistance and no fold-change. When trimethoprim 
mutants were susceptibility tested against colistin, the largest range of fold change was 
observed (-4 to +2) Table 9. As seen in the heat maps, mutants do not always display 
similarities, even if they are generated by the same selection concentration, the MIC 
differences between the WT are mutant similar, or if they are originated from the same 
parental strain. The network differences are likely the result of variation in the genetic 
background (Imamovic and Sommer, 2013).  
 
All of the trimethoprim-selected mutants are defined as resistant, except for 44.8TRI, 
which had a MIC of 2 µg/mL. Interestingly, this isolate in within the ECOFF value range of 
0.064µg/mL to 2µg/mL, which defines it still as sensitive. Despite these properties, 44.8 
TRI tends to show the same collateral networks as the six other trimethoprim mutants 
that are defined as resistant. Even though 44.8TRI is defined as a sensitive, the MIC has 
increased compared to its ancestral strain (MIC = 1 µg/mL) and thus the susceptibility 
towards trimethoprim is decreased. This indicates that the isolate is mutated even though 
it is still defined as sensitive, and displaying similar networks as resistant mutants. As 
seen in Table 6, the MIC of 75.3 displays a ≥ 128-fold change meanwhile 44.8 shows a 2-
fold change compared to MIC WT. The reason for the big range in fold change may indicate 
different mutation affecting trimethoprim MIC. 
 
5.1.2 How do the results compare to existing literature. 
Most of the trimethoprim mutants in this thesis had MICs above the clinical breakpoint. 
Ciprofloxacin and nitrofurantoin mutants display MICs below the clinical breakpoint, and 
are not defined as resistant. All isolates in the thesis were selected at just one 
concentration, and are therefore most likely single-step mutants. Imamovic and Sommer 
(Imamovic and Sommer, 2013) isolated all mutants above the clinical breakpoint and in 





to stronger selection pressure than applied in this study. Interestingly, my findings of 
almost identical collateral sensitivity networks between trimethoprim resistance 
mutants in different E. coli strains resulting in increased sensitivity towards 
aminoglycosides and mecillinam contrasts the findings in (Imamovic and Sommer, 2013). 
These authors reported trimethoprim resistant mutants that displayed 2-4 fold MIC 
increases in susceptibility to gentamycin, kanamycin, ciprofloxacin, and nitrofurantoin. 
No change in susceptibility was seen towards tetracycline and colistin. The only similarity 
to the results presented here was a 2-fold increase of MIC when trimethoprim isolates 
were susceptibility tested with nitrofurantoin. Since the selection pressure applied in 
Imamovic and Sommers paper differed from this thesis, the number of mutations in an 
isolate can vary and the collateral networks thereby as well. Moreover, another difference 
of great importance was between the strains used to generate mutants. One of the strains 
Imamovic and Sommer used was E. coli MG1655. This is a lab strain originally derived 
from the K-12 strain in 1920s from a stool sample of a diphtheria patient (Madison, 2002-
2015). The antimicrobial sensitivity can vary between different strains of E. coli. Since we 
used clinical UTI strains in this thesis, the differing results from Imamovic and Sommer 
could be expected. 
Another recent study (Oz et al., 2014) selected mutants from E. coli MG1655 as well, but 
in two groups. Following “mild” and “strong” antimicrobial selection pressure. The group 
with strongly selected mutants tended to have a higher number of mutations, but the level 
of resistance was equal to both groups. Increased collateral sensitivity and resistance 
networks were also seen in this group compared to the mild selection pressure-group. Oz 
et. al. (Oz et al., 2014) displayed no change in collateral networks when trimethoprim 
isolates were susceptibility tested with ciprofloxacin. On the background of the discussion 
above, the resemblance might be accidental. Further studies with larger and more 








5.2 Generation of mutants 
The degree of difficulty to obtain spontaneous mutants varied according to the 
antimicrobial used. Differences in resistance development are primarily linked to the 
number of mutations needed to achieve a given MIC. A factor that also may affect the level 
of difficulty to generate mutants is whether the antimicrobial is bactericidal or 
bacteriostatic. Ciprofloxacin and nitrofurantoin are bactericidal drugs while 
trimethoprim is a bacteriostatic drug. It is therefore more easy to evolve mutants for 
trimethoprim (Stratton, 2003). This might be due to the fact that trimethoprim simply 
prevents bacteria from growing and depends on the action of the immune system to 
contribute to the removal of the pathogen. Since no immune system is present on an agar 
plate, the development of spontaneous mutants may occur even easier. In addition, a note 
to consider is that most of the trimethoprim selected mutants had MICs above 32 µg/mL, 
which indicates a high-level of resistance. None of the ciprofloxacin and nitrofurantoin 
mutants was defined as high-level mutations.  
It was most difficult to generate nitrofurantoin mutations mainly because of 
nitrofurantoin’s light sensitivity. Even though the nitrofurantoin plates were exposed to 
a minimum of light, we had problems with degradation of the antimicrobial. This allowed 
even the WT to grow on LBA plates with nitrofurantoin, and therefore only one mutant 
was confirmed. 
Mutated isolates can also be generated in LB liquid media (Munck et al., 2014, Rodriguez 
de Evgrafov et al., 2015). In this thesis, solid agar plates (LBA) were used. The advantage 
of using liquid media is not the need of an overnight culture, on the other hand when using 
solid agar plates contaminations may be detected by the eye or the smell. This advantage 
applies as well for gradient plating, but the procedure can be cumbersome. 
Five strains were used in this study, and this number is high compared to other studies. 
Similar studies used one or two strains for studying collateral networks (Imamovic and 
Sommer, 2013, Oz et al., 2014, Szybalski and Bryson, 1952, Lazar et al., 2013, Munck et al., 
2014, Rodriguez de Evgrafov et al., 2015, Kim et al., 2014). When using several strains, the 





Using LB media or LBA plates, allows the bacteria to grow under perfect conditions and 
temperature. These in vitro conditions do not create the most realistic picture of how 
bacteria will act when present in the human body. An immune system will, in addition to 
an antimicrobial treatment, help to overcome the pathogen. If future studies are 
performed in vivo, the collateral networks may differ from the findings in vitro.  
 
5.3 Species confirmation 
In this study, the aim was to verify that mutants of E. coli were isolated, and not 
contaminants. RAPD PCR was well suited for this task the technique is fast, simple and 
inexpensive. Additionally, it does not require DNA sequence knowledge and the same 
primer can be used for a number of bacteria. The evolutionary development and 
diversification of the mutants can also be visualized. Some of the disadvantages of using 
RAPD PCR are that slight alterations in, for example, temperature, pH and time interval 
can cause changes in the binding sites for the primer and thereby which sequences are 
amplified. Just variations of common laboratory equipment can cause this result (Anal, 
2011). 
Some of the samples that were present in the gel electrophoresis pictures showed weak 
bands that might imply that amplification of the sample was reduced during the PCR 
reaction. The water control often showed bands on the gel pictures. As explained in (Pan 
et al., 1997), this is normal because of the M13 primer’s ability of easily binding to any 
DNA present in the water (Figure 6). Thus, a trace amount of DNA in polymerase and/or 
primer solutions would show banding patterns as previously described. 
Other methods of strain typing like DNA sequencing and Pulsed-Field gel electrophoresis 
(PFGE) are more often used. PFGE is often referred as the “gold standard” because of its 
extent of strain discrimination and its accuracy. When using DNA sequencing, you can 
determine all the way down to the genotype. And by using PFGE you can determine the 
bacterial strain. 
A study tested how appropriate RAPD PCR is as a technique. They suggest a minimum of 
two primers when using RAPD and always running a PFGE as a security check (Larrasa et 
al., 2004). Studies with same purpose as this thesis used genome sequencing to identify 





et al., 2015). For later use, I would prefer the use of PFGE or genome sequencing when 
detecting mutations. 
 
5.4 Antimicrobial susceptibility testing 
Normally, when doing E-tests, it is done by three replicates. In this thesis, only one parallel 
was carried out due to lack of equipment. By doing plural replicates the result becomes 
more reliable.  
Determination of MIC can be done by dilution in 96-well plates. This is a more demanding 
procedure due to the quantity of dilutions that is necessary. The E-test is a much easier 
method, but is far more expensive. 
When carrying out E-tests, different types of agar were applied. To measure MIC for 
ancestral strains and mutants, regular LB Agar was used. When examination of collateral 
networks, MHA2 was adopt. This agar is more suited for susceptibility testing. When this 
agar was not chosen consequently for all susceptibility tests, this could have affected the 
results. This is especially true for trimethoprim as extra thymine in the LB media reduces 










Future perspectives include extensive determination of collateral sensitivity networks in 
a clinical strain collection with and without pre-existing resistance determination. When 
expanding the study it is easier to make broader conclusions. A proper statistic analyze 
will allow validated conclusions. 
The insertion of resistant plasmids is also interesting and clinically relevant, when 
studying different gene variations and their effect on collateral networks.  
When this theory has enough studies as a support, the project may be carried out as a 







The results in this thesis suggest the presence of collateral networks between 
antimicrobials used to treat UTIs as well as other diseases. These findings may be the 
starting point for evidence-based antimicrobial stewardship that may in the future affect 
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8.1 Isolated mutants 
Table 14: Generated trimethoprim mutants. Raw material from MIC readings (with no 













  0.75 
Nr. 2.1 4 + ≥ 32 
Nr. 2.2 4 + ≥ 32 
Nr. 2.3 4 + ≥ 32 
Nr. 2.4 4 + ≥ 32 
Strain K56-16 
 
-  0.75 
Nr. 16.5 4 + ≥ 32 
Nr. 16.8 4 + ≥ 32 
Nr. 16. 9 4 + ≥ 32 
Nr 16.10 4 + ≥ 32 
Nr. 16.11 4 + ≥ 32 
Nr. 16.14 4 + ≥ 32 
Nr. 16.15 4 + ≥ 32 
Nr. 16.16 4 + ≥ 32 
Nr. 16.17 4 + ≥ 32 
Nr. 16.18 4 + ≥ 32 
Nr. 16.20 4 + ≥ 32 
Nr. 16.22 4 + ≥ 32 

















  0.75 
Nr. 44.7 4 + ≥ 32 
Nr. 44.8 4 + 1.5 
Nr. 44.9 4 + 1.5 
Nr. 44.13 4 + 6 
Nr. 44.14 4 + 16 
Nr. 44.18 4 + 3 
Nr. 44.20 4 + ≥ 32 
Strain K56-68 
 
  0.38 
Nr. 68.1 3 ID ND 
Nr. 68.2 3 ID ND 
Nr. 68.3 3 + ≥ 32 
Nr. 68.4 3 ID ND 
Nr. 68.13 4 + ≥ 32 
Strain K56-75   0.25 
Nr. 75.1 4 + 4 
Nr. 75.2 3 + ≥ 32 
Nr. 75.3 3 + ≥ 32 
Nr. 75.4 3 + ≥ 32 
Nr. 75.5 3 + ≥ 32 
Nr. 75.6 3 + ≥ 32 
Nr. 75.7 3 + ≥ 32 
Nr. 75.8 3 + ≥ 32 
Nr. 75.9 3 + ≥ 32 
Nr. 75.10 3 + ≥ 32 
Nr. 75.11 3 + ≥ 32 





Table 15: Generated ciprofloxacin mutants. Raw material from MIC readings (with no 
two-fold dilution adjustment) 
Strain or isolate Selection 
(µg/mL CIP) 




  0.75 
Nr. 2.1 0.1 + 0.5 
Nr. 2.2 0.1 + 0.38 
Nr. 2.3 0.1 + 0.38 
Nr. 2.5 0.1 + 0.5 
Nr. 2.7 0.1 + 0.25 
Nr. 2.8 0.1 + 0.38 
Nr. 2.9 0.1 + 0.38 
Nr. 2.10 0.1 + 0.5 
Strain K56-16 
 
  0.006 
Nr. 16.1 0.1 + 0.25 
Nr. 16.2 0.1 + 0.25 
Nr. 16.3 0.1 + 0.19 
Nr. 16.4 0.1 ID ND 
Nr. 16.5 0.1 ID ND 
Nr. 16.6 0.1 ID ND 
Nr. 16.9 0.1 + 0.25 
Nr. 16.10 0.1 + 0.19 
Nr. 16.11 0.1 + 0.38 
Nr. 16.13 0.1 + 0.19 
Nr. 16.14 0.1 + 0.25 
Nr. 16.15 0.1 + 0.25 







Strain Selection  
(ug/mL CIP) 




  0.008 
Nr. 44.1 0.1 + 0.5 
Nr. 44.2 0.1 + 0.75 
Nr. 44.4 0.1 + 0.38 
Nr. 44.5 0.1 + 0.5 
Nr. 44.6 0.1 + 0.5 
Nr. 44.7 0.1 + 0.5 
Nr. 44.8 0.1 + 0.5 
Strain K56-68 
 
  0.008 
Nr. 68.1 0.1 + 0.38 
Nr. 68.2 0.1 ID 0.38 
Nr. 68.3 0.1 + 0.38 






Nr. 75.1 0.1 + 0.25 
Nr. 75.2 0.1 + 0.25 
Nr. 75.3 0.1 ID ND 
Nr. 75.7 0.1 + 0.19 
 
Abbreviations and symbols:  









8.2 MIC values used in “trimethoprim heat map” 
 
Table 16: Overview of MIC values of the different strain WTs and trimethoprim mutants 
when tested to seven different antimicrobials; gentamycin, kanamycin, tetracycline, 
colistin, nitrofurantoin, mecillinam and ciprofloxacin. 
  Minimal Inhibitory Concentration (µg/mL) 
Strain Mutant GEN KAN TET COL NIT MEC CIP 
K56-2 WT 1 4 4 1 8 0.25 0.008 
 2.1 TRI 0.25 2 0.5 1 16 0.125 0.008 
K56-16 WT 2 4 4 1 4 1 0.008 
 16.5 TRI 0.25 2 1 1 8 0.25 0.008 
K56-44 WT 2 8 2 0.5 8 1 0.008 
 44.7 TRI 0.19 2 0.5 1 8 0.25 0.008 
 44.8 TRI 0.25 2 0.5 1 8 0.125 0.008 
 44.14 TRI 0.25 1 0.25 1 8 0.25 0.008 
K56-68 WT 4 8 2 1 8 0.5 0.008 
 68.13 TRI 0.5 2 0.5 1 8 0.25 0.008 
K56-75 WT 2 8 2 0.5 4 0.25 0.008 
 75.3 TRI 0.25 2 0.5 0.125 8 0.125 0.008 
 
Abbreviations: GEN – Gentamycin, KAN – Kanamycin, TET – Tetracycline, COL – Colistin, 






8.3 MIC values used in “ciprofloxacin heat map”  
 
Table 17: Overview of MIC values of the different strains’ WT and ciprofloxacin 
mutants, when tested to seven different antimicrobials; gentamycin, kanamycin, 
tetracycline, colistin, nitrofurantoin, mecillinam and trimethoprim. 
  Minimal Inhibitory Concentration (µg/mL) 
Strain Mutant GEN KAN TET COL NIT MEC TRI 
K56-2 WT 1 4 4 1 8 0.25 1 
 2.3 CIP 0.5 2 0.5 1 16 0.25 0.5 
 WT 1 4 4 1 8 0.25 1 
 2.5 CIP 0.5 2 0.5 1 16 0.125 0.5 
 WT 1 4 4 1 8 0.25 1 
 2.7 CIP 0.25 2 0.5 1 16 0.125 0.5 
K56-16 WT 2 4 4 1 4 1 1 
 16.1 CIP 0.25 2 0.5 1 4 0.125 0.5 
 WT 2 4 4 1 4 1 1 
 16.3 CIP 0.25 2 0.5 1 8 0.25 0.25 
 WT 2 4 4 1 4 1 1 
 16.11 CIP 0.25 2 0.5 1 8 0.125 0.25 
K56-44 WT 2 8 2 0.5 8 1 1 
 44.4 CIP 0.5 1 0.5 1 8 0.25 0.25 
 WT 2 8 2 0.5 8 1 1 
 44.5 CIP 0.5 2 0.5 1 8 0.125 0.25 
K56-68 WT 4 8 2 1 8 0.5 0.5 
 68.1 CIP 0.5 2 0.5 1 8 0.25 0.25 
K56-75 WT 2 8 2 0.5 4 0.25 0.25 
 75.1CIP 0.5 2 0.5 1 8 0.25 0.25 
 
Abbreviations: GEN – Gentamycin, KAN – Kanamycin, TET – Tetracycline, COL – Colistin, 






8.4 MIC values used in “nitrofurantoin heat map”  
 
Table 18: Overview of MIC values of the WT and nitrofurantoin mutant originating from 
the K56-2 strain, when tested to seven different antimicrobials; gentamycin, kanamycin, 
tetracycline, colistin, trimethoprim, mecillinam, and ciprofloxacin.  
 
Strain  Minimal Inhibitory Concentration (µg/mL)  
 Mutant  GEN  KAN TET COL TRI MEC CIP 
K56-2 WT 1 4 4 1 1 0.25 0.008 
 2.3 NIT 0.5 2 2 2 0.5 0.5 0.016 
 
Abbreviations: GEN – Gentamycin, KAN – Kanamycin, TET – Tetracycline, COL – Colistin, 







8.5 MIC values used in “double mutant heat map”  
 
Table 19: Overview of MIC values of the different strain WT and the double mutants 
originating from the respective strains, when tested to six different antimicrobials; 
gentamycin, kanamycin, tetracycline, colistin, nitrofurantoin, and mecillinam 
 Minimal Inhibitory Concentration (µg/mL)  
Double 
Mutant 
GEN KAN TET COL NIT MEC 
WT 1 4 4 1 8 0.25 
2.1 CIPTRI 0.5 2 2 1 16 0.25 
WT 4 8 2 1 8 0.5 
68.1 CIPTRI 0.5 2 0.5 1 16 0.25 
WT 2 8 2 0.5 4 0.25 
75.1 CIPTRI 1 4 2 1 16 0.125 
Abbreviations: GEN – Gentamycin, KAN – Kanamycin, TET – Tetracycline, COL – Colistin, 
NIT – Nitrofurantoin, MEC – Mecillinam, TRI – Trimethoprim, CIP – Ciprofloxacin.  
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